

Antineoplastic Therapy and Immunotherapy Course

UPMC Hillman Cancer Center: Virtual via MS Teams

Day One: Friday, August 16, 2024

Day Two: Wednesday, August 21, 2024

Day Three: Friday, August 23, 2024

Day Four: Wednesday, August 28, 2024

Test Date: Friday, September 6, 2024

Learning Objectives

After participation in this activity, the learner will be able to:

- Compare and contrast the mechanism of action between antineoplastic therapy and immunotherapy.
- Recall the side effect profiles for the different classes of antineoplastic agents and immunotherapies.
- Recall nursing care considerations for patients receiving antineoplastic therapy and immunotherapy.
- Compare and contrast the mechanisms of action, side effect profile, complications, and management of side effects for patients receiving novel treatment modalities including Car T-cell therapy, BiTE therapy, and TIL-cell therapy.
- Describe the role that chemotherapy protectants play in the treatment of cancer.
- Recall patient barriers to adherence of oral cancer medications.
- Apply principles of antineoplastic therapy drug administration in calculating drug doses to include calculation of body surface area (BSA), absolute neutrophil count (ANC), creatinine clearance (Cr Cl) and carboplatin dosing.
- Describe the steps to ensure safe administration of antineoplastic and immunotherapy agents.
- Identify assessment priorities to effectively manage patient symptoms, dose-limiting toxicities, and adverse effects of antineoplastic therapy and immunotherapy.
- Recognize relevant resources for proper use of personal protective equipment (PPE) and excretion precautions.
- Prioritize the appropriate interventions for the management of hypersensitivity reactions.
- Describe the appropriate interventions for the management of vesicant extravasation.
- Discuss the differences between cancer genetics and cancer genomics.
- Identify the role that growth factors play when treating oncology patients.
- Recall strategies to prevent medication errors.

Agenda

Day One: Friday, August 16, 2024

7:30 am	Registration and Microsoft Teams Login	
8:00 am	Welcome and Course Overview	Lynne O'Connor, MSN, RN, OCN
8:20 am	Principles of Antineoplastic Drug Therapy	Ernie Sanchez, PharmD
9:20 am	Antineoplastic Therapy Administration	Markie Rearick, MSN, RN, BMTCN
10:35 am	Break	
10:45 am	Extravasation	Nancy Birus, MSN, RN, OCN
11:15 am	Hypersensitivity	Alyssa Owens, MPAS, PA-C
11:50 am	Lunch	
12:30 pm	Error Prevention	Amy DiMaggio, MSN, RN, OCN
1:10 pm	Build Your Knowledge Case Studies	Lynne O'Connor, MSN, RN, OCN
2:00 pm	Break	
2:10 pm	Alkylating Agents	Trish Seaman, MSN, RN, CMSRN
3:10 pm	Chemotherapy Protectants	Lynne O'Connor, MSN, RN, OCN
3:45 pm	Adjournment	Lynne O'Connor, MSN, RN, OCN

Agenda

Day 2: Wednesday, August 21, 2024

7:30 am	Registration and Microsoft Teams Login	
8:00 am	Welcome and Course Overview	Lynne O'Connor, MSN, RN, OCN
8:05 am	Genetics vs. Genomics	Melissa K. Bourdus, MS, CGC
8:40 am	Antimetabolites	Tim George, PharmD, BCOP
9:40 am	Break	
9:50 am	Antitumor Antibiotics	Steve Moretti, PharmD
10:50 am	Cytokines, L Asparaginase, and Vaccine Therapy	Tim George, PharmD, BCOP
11:50 am	Lunch	
12:20 pm	Growth Factors	Emily Mueseler, MPAS, PA-C
12:50 pm	Understanding Organ Toxicity: Management and Adverse Events of Chemotherapy	Linda Pfeifer, CRNP, RN
1:50 pm	Break	
2:00 pm	Miscellaneous Agents	Tim Brenner, PharmD, BCOP
4:00 pm	Adjournment	Lynne O'Connor, MSN, RN, OCN

Agenda

Day 3: Friday, August 23, 2024

7:30 am	Registration and Microsoft Teams Login	
8:00 am	Welcome and Course Overview	Lynne O'Connor, MSN, RN, OCN
8:20 am	Hormone Therapy: Breast Cancer	Courtney Stetor, MPAS, PA-C
8:50 am	Hormone Therapy: Prostate Cancer	Tom Boyer, PA-C
9:30 am	Adoptive Cellular Therapy and BiTE Therapy	Shrina Duggal, PharmD, BCOP
10:30 am	Break	
10:40 am	Monoclonal Antibodies: Part One	Melissa Bastacky, PharmD, BCOP
12:00 pm	Lunch	
12:30 pm	Monoclonal Antibodies: Part Two	Melissa Bastacky, PharmD, BCOP
1:30 pm	Tyrosine Kinase Inhibitors: Part One	Amanda Agnew, PharmD, BCOP
2:25 pm	Break	
2:35 pm	Tyrosine Kinase Inhibitors: Part Two	Jason Steele, PharmD, BCOP
3:40 pm	Oral Adherence	Nancy Birus, MSN, RN, OCN
4:15 pm	Adjournment	

Agenda

Day 4: Wednesday, August 28, 2024

7:30 am	Registration and Microsoft Teams Login	
8:00 am	Welcome and Course Overview	Lynne O'Connor, MSN, RN, OCN
8:20 am	Plant Alkaloids	Marissa Lamary, PA-C
9:00 am	Homework Review	Lynne O'Connor, MSN, RN, OCN
9:45 am	Break	
9:55 am	Case Study	Brittini Prosdocimo, MSN, RN, BMTCN
10:45 am	Review/Jeopardy	Amy DiMaggio, MSN, RN, OCN Lynne O'Connor, MSN, RN, OCN Brittini Prosdocimo, MSN, RN, BMTCN
11:45 am	Post Class Instructions	Lynne O'Connor, MSN, RN, OCN
12:00 pm	End of Class/Adjournment	Lynne O'Connor, MSN, RN, OCN

Course Exam

UPMC Employees:

You will take course exam on your business unit as specified by your manager. The electronic test will be taken virtually in HR Direct - Learning on Friday, September 6, 2024. The following information must be provided to course director by **Friday, August 23, 2024 (Day 3) via email to Lynne O'Connor at OConnorLJ@upmc.edu**

- Name of exam proctor and contact information
- Test date (if other than scheduled test date)

Non-UPMC Attendees:

You will complete a paper test at your business unit as directed by your manager on the same day as the UPMC employees. The following information must be provided to course director by **Friday, August 23, 2024 (Day 3) via email to Lynne O'Connor at OConnorLJ@upmc.edu**

- Name of exam proctor and contact information
- Test date (if other than scheduled test date)

Faculty Listing

*Amanda Agnew, PharmD, BCPS,
BCOP
Clinical Oncology Pharmacist
UPMC Hillman Cancer Center*

*Melissa Bastacky, PharmD, BCOP
Clinical Pharmacy Specialist
UPMC Hillman Cancer Center*

*Nancy Birus, MSN, RN, OCN
Clinical Education Specialist
UPMC Hillman Cancer Center*

*Melissa K. Bourdus, MS, CGC
Genetics Counselor
Special Genetic Counsel
UPMC Magee-Womens Hospital*

*Tom Boyer, PA-C
Physician Assistant
UPMC Hillman Cancer Center*

*Tim Brenner, PharmD, BCOP
Clinical Pharmacy Specialist
UPMC Hillman Cancer Center*

*Amy DiMaggio, MSN, RN, OCN
Clinical Education Specialist
UPMC Hillman Cancer Center*

*Shrina Duggal, PharmD, BCOP
Lead Clinical Oncology Pharmacist
UPMC Hillman Cancer Center*

*Timothy George, PharmD, BCOP
Clinical Pharmacy Specialist
UPMC Hillman Cancer Center*

*Marissa Lamary, PA-C
Physician Assistant
UPMC Hillman Cancer Center
UPMC Shadyside*

*Steven Moretti, PharmD
Oncology Consultant Pharmacist
Investigational Drug Service
UPMC Hillman Cancer Center*

*Emily Mueseler, MPAS, PA-C
Physician Assistant
UPMC Hillman Cancer Center*

*Lynne O'Connor, MSN, RN, OCN
Clinical Education Specialist
UPMC Hillman Cancer Center*

*Alyssa Owens, MPAS, PA-C
Physician Assistant
UPMC Hillman Cancer Center*

*Linda Pfeifer, CRNP, RN
Nurse Practitioner
UPMC Hillman Cancer Center*

*Brittini Prosdocimo, MSN, RN, BMTCN
Advanced Clinical Education Specialist
UPMC Hillman Cancer Center*

*Markie Rearick, MSN, RN, BMTCN
Clinical Education Specialist
UPMC Shadyside*

*Ernest M. Sanchez, Pharm.D.
Lead Pharmacist of Oncology
Operations, Department of
Pharmacy
UPMC Shadyside Hospital*

*Trish Seaman, MSN, RN, CMSRN
Nurse Educator, Central PA
UPMC Hillman Cancer Center*

*Jason Steele, PharmD, BCOP
Oncology Clinical Pharmacist
UPMC Hillman Cancer Center*

*Courtney Stetor, MPAS PA-C
Physician Assistant
UPMC Hillman Cancer Center*

Contact Hours

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Pittsburgh has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 25.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

The maximum number of hours awarded for this Continuing Nursing Education activity is 25.25 contact hours.

To receive 25.25 Contact Hours, the learner must sign into each class day via Microsoft Teams, attend all four class days, and pass the exam with an 80% or greater. Following test completion, the learner will complete the evaluation on the CCE site and claim credit.

Disclosure of Conflicts of Interest

All individuals in a position to control the content of this education activity are required to disclose all relevant financial relationships with any proprietary entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients.

The following information was provided:

Amanda Agnew, Nancy Birus, Melissa K. Bourdius, Thomas G. Boyer, Timothy Brenner, Amy DiMaggio, Marissa Lamary, Emily Mueseler, Lynne O'Connor, Alyssa Owens, Linda Pfeifer, Markie Rearick, Brittni Prosdocimo, Ernest Sanchez, Trish Seaman, Courtney Stetor, and the planning committee for this activity did not have any relevant financial relationships with a commercial interest.

The following information was disclosed:

Melissa Bastacky: Stockholder: CVS Health

Shrina Duggal: Consultant Up ToDate; CE Speakers Bureau: Astellas, Pfizer, Incyte

Timothy George: Stockholder: Syros Pharmaceuticals, Valneva

Brian Miller: Grant/Research Support: F-Star Therapeutics, HiberCell Inc., Istari Oncology, Inc

Jason Steele: Stockholder: Abbvie